MEOBF (Mesoblast) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEOBF Mesoblast Ltd MEOBF
47 GF Score
Price $1.70
GF Value $0.16
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mesoblast FFO per Share?

FFO per Share only applies to REITs.

MEOBF
47GF Score
Mesoblast Ltd MEOBF
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mesoblast (MEOBF) Overvalued in 2026?

Based on GuruFocus' analysis, Mesoblast stock appears to be overvalued. The current stock price of $1.70 is trading 962.5% above its estimated GF Value™ of $0.16. GuruFocus considers Mesoblast to be Significantly Overvalued.

Key valuation signals for MEOBF:

  • FFO per Share:
  • GF Value™: $0.16 vs. price of $1.70 (962.5% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the MEOBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
47GF Score

Get the complete analysis for MEOBF

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.70
Price
$0.16
GF Value